These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 37477863)

  • 1. Interim analysis of post-marketing surveillance of ravulizumab for paroxysmal nocturnal hemoglobinuria in Japan.
    Usuki K; Ikezoe T; Ishiyama K; Kanda Y; Gotoh A; Hayashi H; Shimono A; Kitajima A; Obara N; Nishimura JI
    Int J Hematol; 2023 Sep; 118(3):311-322. PubMed ID: 37477863
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term safety and efficacy of ravulizumab in patients with paroxysmal nocturnal hemoglobinuria: 2-year results from two pivotal phase 3 studies.
    Kulasekararaj AG; Griffin M; Langemeijer S; Usuki K; Kulagin A; Ogawa M; Yu J; Mujeebuddin A; Nishimura JI; Lee JW; Peffault de Latour R;
    Eur J Haematol; 2022 Sep; 109(3):205-214. PubMed ID: 35502600
    [TBL] [Abstract][Full Text] [Related]  

  • 3. One-year outcomes from a phase 3 randomized trial of ravulizumab in adults with paroxysmal nocturnal hemoglobinuria who received prior eculizumab.
    Kulasekararaj AG; Hill A; Langemeijer S; Wells R; González Fernández FA; Gaya A; Ojeda Gutierrez E; Piatek CI; Mitchell L; Usuki K; Bosi A; Brodsky RA; Ogawa M; Yu J; Ortiz S; Röth A; Lee JW; Peffault de Latour R
    Eur J Haematol; 2021 Mar; 106(3):389-397. PubMed ID: 33301613
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase 3 Study of Subcutaneous Versus Intravenous Ravulizumab in Eculizumab-Experienced Adult Patients with PNH: Primary Analysis and 1-Year Follow-Up.
    Yenerel MN; Sicre de Fontbrune F; Piatek C; Sahin F; Füreder W; Ortiz S; Ogawa M; Ozol-Godfrey A; Sierra JR; Szer J
    Adv Ther; 2023 Jan; 40(1):211-232. PubMed ID: 36272026
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term follow-up of patients with paroxysmal nocturnal hemoglobinuria treated with eculizumab: post-marketing surveillance in Japan.
    Ikezoe T; Noji H; Ueda Y; Kanda Y; Okamoto S; Usuki K; Matsuda T; Akiyama H; Shimono A; Yonemura Y; Kawaguchi T; Chiba S; Kanakura Y; Nishimura JI; Ninomiya H; Obara N
    Int J Hematol; 2022 Apr; 115(4):470-480. PubMed ID: 35146630
    [TBL] [Abstract][Full Text] [Related]  

  • 6. One-year efficacy and safety of ravulizumab in adults with paroxysmal nocturnal hemoglobinuria naïve to complement inhibitor therapy: open-label extension of a randomized study.
    Schrezenmeier H; Kulasekararaj A; Mitchell L; Sicre de Fontbrune F; Devos T; Okamoto S; Wells R; Rottinghaus ST; Liu P; Ortiz S; Lee JW; Socié G
    Ther Adv Hematol; 2020; 11():2040620720966137. PubMed ID: 33178408
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Japanese patient preferences between ravulizumab and eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria].
    Ishiyama K; Usuki K; Ikezoe T; Gotoh A; Myren KJ; Tomazos I; Shimono A; Ninomiya H; Sakurai M; Nakao S; Nishimura JI
    Rinsho Ketsueki; 2023; 64(1):9-17. PubMed ID: 36775313
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor-experienced adult patients with PNH: the 302 study.
    Kulasekararaj AG; Hill A; Rottinghaus ST; Langemeijer S; Wells R; Gonzalez-Fernandez FA; Gaya A; Lee JW; Gutierrez EO; Piatek CI; Szer J; Risitano A; Nakao S; Bachman E; Shafner L; Damokosh AI; Ortiz S; Röth A; Peffault de Latour R
    Blood; 2019 Feb; 133(6):540-549. PubMed ID: 30510079
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ravulizumab for the treatment of paroxysmal nocturnal hemoglobinuria.
    Lee JW; Kulasekararaj AG
    Expert Opin Biol Ther; 2020 Mar; 20(3):227-237. PubMed ID: 32011183
    [No Abstract]   [Full Text] [Related]  

  • 10. Results from multinational phase 3 studies of ravulizumab (ALXN1210) versus eculizumab in adults with paroxysmal nocturnal hemoglobinuria: subgroup analysis of Japanese patients.
    Ishiyama K; Nakao S; Usuki K; Yonemura Y; Ikezoe T; Uchiyama M; Mori Y; Fukuda T; Okada M; Fujiwara SI; Noji H; Rottinghaus S; Aguzzi R; Yokosawa J; Nishimura JI; Kanakura Y; Okamoto S
    Int J Hematol; 2020 Oct; 112(4):466-476. PubMed ID: 32869125
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety of current treatments for paroxysmal nocturnal hemoglobinuria.
    Lee SE; Lee JW
    Expert Opin Drug Saf; 2021 Feb; 20(2):171-179. PubMed ID: 33249943
    [No Abstract]   [Full Text] [Related]  

  • 12. Predictors for improvement in patient-reported outcomes: post hoc analysis of a phase 3 randomized, open-label study of eculizumab and ravulizumab in complement inhibitor-naive patients with paroxysmal nocturnal hemoglobinuria.
    Schrezenmeier H; Kulasekararaj A; Mitchell L; de Latour RP; Devos T; Okamoto S; Wells R; Popoff E; Cheung A; Wang A; Tomazos I; Patel Y; Lee JW
    Ann Hematol; 2024 Jan; 103(1):5-15. PubMed ID: 37804344
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dosing Patterns of Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with Ravulizumab in the United States: A Retrospective Claims-Based Analysis.
    Cheng WY; Fishman J; Yenikomshian M; Mahendran M; Kunzweiler C; Vu JD; Duh MS
    Adv Ther; 2024 Jan; 41(1):413-430. PubMed ID: 37999832
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost burden of breakthrough hemolysis in patients with paroxysmal nocturnal hemoglobinuria receiving ravulizumab versus eculizumab.
    Tomazos I; Sierra JR; Johnston KM; Cheung A; Brodsky RA; Weitz IC
    Hematology; 2020 Dec; 25(1):327-334. PubMed ID: 32856539
    [No Abstract]   [Full Text] [Related]  

  • 15. Real-world safety profile of eculizumab in patients with paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, or generalized myasthenia gravis: an integrated analysis of post-marketing surveillance in Japan.
    Nishimura JI; Kawaguchi T; Ito S; Murai H; Shimono A; Matsuda T; Fukamizu Y; Akiyama H; Hayashi H; Nakano T; Maruyama S
    Int J Hematol; 2023 Oct; 118(4):419-431. PubMed ID: 37515657
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative Effectiveness of Pegcetacoplan Versus Ravulizumab and Eculizumab in Complement Inhibitor-Naïve Patients with Paroxysmal Nocturnal Hemoglobinuria: A Matching-Adjusted Indirect Comparison.
    Wong R; Fishman J; Wilson K; Yeh M; Al-Adhami M; Zion A; Yee CW; Huynh L; Duh MS
    Adv Ther; 2023 Apr; 40(4):1571-1589. PubMed ID: 36750531
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: the 301 study.
    Lee JW; Sicre de Fontbrune F; Wong Lee Lee L; Pessoa V; Gualandro S; Füreder W; Ptushkin V; Rottinghaus ST; Volles L; Shafner L; Aguzzi R; Pradhan R; Schrezenmeier H; Hill A
    Blood; 2019 Feb; 133(6):530-539. PubMed ID: 30510080
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics, pharmacodynamics, efficacy, and safety of ravulizumab in pediatric paroxysmal nocturnal hemoglobinuria.
    Chonat S; Kulagin A; Maschan A; Bartels M; Buechner J; Punzalan R; Richards M; Ogawa M; Hicks E; Yu J; Baruchel A; Kulasekararaj AG
    Blood Adv; 2024 Jun; 8(11):2813-2824. PubMed ID: 38551806
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative effectiveness of pegcetacoplan versus ravulizumab in patients with paroxysmal nocturnal hemoglobinuria previously treated with eculizumab: a matching-adjusted indirect comparison.
    Bhak RH; Mody-Patel N; Baver SB; Kunzweiler C; Yee CW; Sundaresan S; Swartz N; Duh MS; Krishnan S; Sarda SP
    Curr Med Res Opin; 2021 Nov; 37(11):1913-1923. PubMed ID: 34445916
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interim analysis of post-marketing surveillance of eculizumab for paroxysmal nocturnal hemoglobinuria in Japan.
    Ninomiya H; Obara N; Chiba S; Usuki K; Nishiwaki K; Matsumura I; Shichishima T; Okamoto S; Nishimura JI; Ohyashiki K; Nakao S; Ando K; Kanda Y; Kawaguchi T; Nakakuma H; Harada D; Akiyama H; Kinoshita T; Ozawa K; Omine M; Kanakura Y
    Int J Hematol; 2016 Nov; 104(5):548-558. PubMed ID: 27464489
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.